MedTrace Logo

Vitamin D Deficiency in Patients With Hypertension

NCT00974922 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-03-09

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effects of Vitamin D replacement and the effects of an approved medication for hypertension, aliskiren (Tekturna), in patients with high blood pressure who have low levels of vitamin D in their blood. The study will compare the effects of vitamin D or aliskiren alone and in combination on 24-hour blood pressure and biochemical parameters.

Conditions

Interventions

DRUG

Aliskiren

150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks

DIETARY_SUPPLEMENT

Cholecalciferol

3000 I.U. once daily for 6 weeks

DIETARY_SUPPLEMENT

Placebo

Placebo for two weeks

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • UConn Health

    lead OTHER

Principal Investigators

  • William B White, M.D. · Pat and Jim Calhoun Cardiology Center, University of Connecticut Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00974922 on ClinicalTrials.gov